IA
YMAB

IndexIQ Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

IndexIQ Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8,025
Closed -$397K – 1336
2020
Q4 		$397K Buy
8,025
+829
+12% +$38.3K 0.01% 494
2020
Q3 		$276K Buy
7,196
+389
+6% +$15.5K 0.01% 449
2020
Q2 		$294K Sell
6,807
-1,281
-16% -$48.4K 0.01% 340
2020
Q1 		$211K Buy
+8,088
New +$235K 0.01% 284

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

IndexIQ Advisors's YMAB Position: Q1 2021 in Review

IndexIQ Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q1 2021, closing a stake of 8,025 shares — an estimated $397K sold.

IndexIQ Advisors first reported a position in YMAB in Q1 2020 and held it in 4 quarters. The position peaked at $397K in Q4 2020. 117 funds tracked by Wall St. Rank hold YMAB as of Q1 2021.

  • IndexIQ Advisors reported no remaining Y-mAbs Therapeutics position as of Q1 2021 after selling out during the quarter.
  • IndexIQ Advisors sold 8,025 Y-mAbs Therapeutics shares in Q1 2021, an estimated $397K.
  • IndexIQ Advisors first reported a position in Y-mAbs Therapeutics in Q1 2020 and held it in 4 quarters.
  • IndexIQ Advisors's Y-mAbs Therapeutics position peaked at $397K in Q4 2020.
  • 117 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2021.

Based on IndexIQ Advisors's 13F filing for Q1 2021, filed 7 May 2021.